Seres Therapeutics' core business segment revolves around the development of microbiome therapeutics, a novel class of biological drugs designed to modulate the colonic microbiome. This segment encompasses a range of research and development activities focused on creating bacterial consortia that functionally interact with host cells and tissues to treat various diseases. Key technologies include advanced culturing techniques, genomic sequencing, and bioinformatics analysis to identify and optimize therapeutic bacterial strains. The therapeutic areas targeted include Clostridium difficile infection (CDI), ulcerative colitis, metastatic melanoma, and other inflammatory and immune-related diseases. The company's lead product candidate, SER-109, has demonstrated promising clinical results in treating CDI, showcasing the potential for microbiome-based therapies to address unmet medical needs. Future opportunities include expanding the pipeline with new microbiome therapeutics for a broader range of diseases and exploring personalized medicine approaches based on individual patient microbiomes.